Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005684
Status:
COMPLETED
Last Update Posted:
2016-05-13
First Post:
2000-05-25
Brief Title:
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Heart Lung and Blood Institute NHLBI
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2005-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To perform a randomized clinical trial comparing continuing one month of treatment with heparin in patients with deep venous thrombosis to standard care using heparin for five days and oral warfarin for three months
Detailed Description:
BACKGROUND
The study a subproject within a SCOR in Thrombosis should help to improve the long-term clinical outcome of patients with proximal deep-vein thrombosis popliteal femoral or iliac vein thrombosis by improving their survival and reducing morbidity from recurrent thromboembolic events and should help to determine if one or more specific biochemical measures including antiphospholipid antibodies and activated factor VII will define a subset of patients at increased risk of recurrent venous thromboembolism
The study is part of a SCOR in Hemostatic and Thrombotic Diseases the RFA for which was released by the NHLBI in April 1994
DESIGN NARRATIVE
Warfarin Trial
A multicenter randomized clinical trial was conducted from March 1996 through January 2001 comparing warfarin therapy for three years to warfarin therapy for three months The study was performed at thirteen participating hospitals in Oklahoma The 600 hundred patients were recruited randomized to either warfarin therapy for three years or warfarin therapy for three months and followed for at least three years The primary outcome measure was total mortality Secondary outcome measures included vascular death objectively documented recurrent venous thromboembolism and bleeding complications major and minor Additional specific aims included determining the prevalence of antiphospholipid antibodies antithrombomodulin antibodies and activated protein C resistance in consecutive patients with proximal-vein thrombosis determining if these measures andor the level of activated factor VII were associated with an increased risk of recurrent venous thromboembolic events and if so whether these events were reduced by continuing long term warfarin treatment These latter specific aims were achieved by performing the laboratory parameters concurrently in patients entered into the clinical trial and relating these measures to the clinical outcomes on long-term follow-up
The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System PRS record
The study a subproject within a SCOR in Thrombosis should help to improve the long-term clinical outcome of patients with proximal deep-vein thrombosis popliteal femoral or iliac vein thrombosis by improving their survival and reducing morbidity from recurrent thromboembolic events and should help to determine if one or more specific biochemical measures including antiphospholipid antibodies and activated factor VII will define a subset of patients at increased risk of recurrent venous thromboembolism
The study is part of a SCOR in Hemostatic and Thrombotic Diseases the RFA for which was released by the NHLBI in April 1994
DESIGN NARRATIVE
Warfarin Trial
A multicenter randomized clinical trial was conducted from March 1996 through January 2001 comparing warfarin therapy for three years to warfarin therapy for three months The study was performed at thirteen participating hospitals in Oklahoma The 600 hundred patients were recruited randomized to either warfarin therapy for three years or warfarin therapy for three months and followed for at least three years The primary outcome measure was total mortality Secondary outcome measures included vascular death objectively documented recurrent venous thromboembolism and bleeding complications major and minor Additional specific aims included determining the prevalence of antiphospholipid antibodies antithrombomodulin antibodies and activated protein C resistance in consecutive patients with proximal-vein thrombosis determining if these measures andor the level of activated factor VII were associated with an increased risk of recurrent venous thromboembolic events and if so whether these events were reduced by continuing long term warfarin treatment These latter specific aims were achieved by performing the laboratory parameters concurrently in patients entered into the clinical trial and relating these measures to the clinical outcomes on long-term follow-up
The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System PRS record
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P50HL054502 | NIH | None | httpsreporternihgovquickSearchP50HL054502 |